DEF 14A: BioLife Solutions Sets Date for 2024 Annual Stockholders Meeting

BioLife Solutions will hold its 2024 Annual Meeting of Stockholders virtually on August 1, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• BioLife Solutions, Inc. will hold its 2024 Annual Meeting of Stockholders on August 1, 2024, at 9:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of June 3, 2024, are entitled to vote on the election of five directors, an advisory vote on executive compensation, and the ratification of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR the director nominees, FOR the approval of executive compensation, and FOR the ratification of Grant Thornton LLP.
• The proxy materials are available online, and stockholders can vote via the Internet, telephone, or mail.
• On the Record Date, there were 46,068,755 shares of Common Stock outstanding and approximately 240 record holders of our Common Stock.
• Additionally, there were 2,474,660 unvested restricted shares of Common Stock outstanding on the Record Date.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it outlines positive corporate governance practices and future goals, it also acknowledges financial underperformance in 2023 and executive compensation adjustments.

Positives

• The company is utilizing virtual stockholder meeting technology to provide ready access and cost savings for stockholders.
• The Board of Directors is actively engaged in corporate governance, with established Audit, Compensation, and Governance and Nominating Committees.
• The company has adopted a Code of Business Conduct and Ethics to promote honest and ethical conduct and compliance with applicable laws and regulations.

Negatives

• The company did not achieve its financial goals for 2023, leading to no bonus payouts for NEOs.
• Several Section 16(a) filings were filed late by directors and executive officers during 2023.
• The company experienced challenging headwinds for the cell and gene therapy industry in 2023.

Risks

• The macroeconomic environment created challenging headwinds for the cell and gene therapy industry.
• Reduced spending across the customer base for both capital equipment and consumables.
• Destocking by customers and distributors in high margin cell processing products.
• Potential for material noncompliance with financial reporting requirements that could trigger the incentive compensation clawback policy.

Future Outlook

The company is keenly focused on continuing to achieve its corporate goals in alignment with its broader purpose to return long-term value to its stockholders and is confident the execution of the initiatives outlined will increase profitability through a focus on differentiated products suited to the complexities of manufacturing cell and gene therapies.

Management Comments

• Roderick de Greef, Chief Executive Officer and Chairman of the Board, expressed gratitude for stockholders' continued support and interest in BioLife Solutions, Inc.

Industry Context

The document notes challenging headwinds for the cell and gene therapy industry, impacting customer spending and inventory levels.

Comparison to Industry Standards

• The Compensation Committee benchmarks executive compensation against a peer group of 20 bioprocessing, life sciences, and biotechnology companies.
• The peer group includes companies such as AngioDynamics, Cardiovascular Systems, Inc, NanoString Technologies, Inc., and Cerus Corporation.

Management Changes

Stakeholder Impact

• Stockholders are encouraged to participate in the Annual Meeting and vote on key proposals.
• Employees may be impacted by compensation adjustments and company performance.
• Customers and suppliers may be affected by the company's strategic focus and financial performance.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.
• The Board will consider stockholder feedback on executive compensation in future deliberations.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Executive Compensation, Board of Directors, Director Election, Grant Thornton, BioLife Solutions